Element Name |
|
bcr_patient_barcode |
|
additional_pharmaceutical_therapy | null |
additional_radiation_therapy | null |
additional_surgery_locoregional_procedure | null |
additional_surgery_metastatic_procedure | null |
adjuvant_postop_targeted_therapy_admin_indicator | null |
age_at_initial_pathologic_diagnosis |
|
ajcc_cancer_staging_handbook_edition |
|
anatomic_site_location_descriptor |
|
axillary_lymph_node_stage_method_type |
|
axillary_lymph_node_stage_other_method_descriptive_text |
|
breast_cancer_optical_measurement_histologic_type |
|
breast_cancer_surgery_margin_status |
|
breast_carcinoma_estrogen_receptor_status |
|
breast_carcinoma_first_surgical_procedure_name |
|
breast_carcinoma_immunohistochemistry_pos_cell_score |
|
breast_carcinoma_progesterone_receptor_status |
|
breast_carcinoma_surgical_procedure_name |
|
breast_neoplasm_other_surgical_procedure_descriptive_text |
|
breast_tumor_clinical_m_stage |
|
breast_tumor_pathologic_grouping_stage |
|
breast_tumor_pathologic_n_stage |
|
breast_tumor_pathologic_t_stage |
|
cytokeratin_immunohistochemistry_staining_method_micrometastasis_indicator |
|
days_to_additional_surgery_locoregional_procedure | null |
days_to_additional_surgery_metastatic_procedure | null |
days_to_birth |
|
days_to_death |
|
days_to_form_completion |
|
days_to_index | null |
days_to_initial_pathologic_diagnosis |
|
days_to_last_followup |
|
days_to_last_known_alive |
|
days_to_new_tumor_event_after_initial_treatment | null |
disease_surgical_margin_status |
|
drugs | null |
er_detection_method_text |
|
er_level_cell_percentage_category |
|
ethnicity |
|
first_nonlymph_node_metastasis_anatomic_site |
|
first_pathologic_diagnosis_biospecimen_acquisition_method_type |
|
first_pathologic_diagnosis_biospecimen_acquisition_other_method_text | null |
first_recurrent_non_nodal_metastatic_anatomic_site_descriptive_text | null |
fluorescence_in_situ_hybridization_diagnostic_procedure_chromosome_17_signal_result_range |
|
gender |
|
her2_and_centromere_17_positive_finding_other_measurement_scale_text |
|
her2_erbb_method_calculation_method_text |
|
her2_erbb_pos_finding_cell_percent_category |
|
her2_erbb_pos_finding_fluorescence_in_situ_hybridization_calculation_method_text |
|
her2_immunohistochemistry_level_result |
|
her2_neu_and_centromere_17_copy_number_analysis_input_total_number_count |
|
her2_neu_and_centromere_17_copy_number_metastatic_breast_carcinoma_analysis_input_total_number_count | null |
her2_neu_breast_carcinoma_copy_analysis_input_total_number |
|
her2_neu_chromosone_17_signal_ratio_value |
|
her2_neu_metastatic_breast_carcinoma_copy_analysis_input_total_number |
|
icd_o_3_histology |
|
icd_o_3_site |
|
immunohistochemistry_positive_cell_score |
|
informed_consent_verified |
|
lab_proc_her2_neu_immunohistochemistry_receptor_status |
|
lab_procedure_her2_neu_in_situ_hybrid_outcome_type |
|
lymph_node_examined_count |
|
metastatic_breast_carcinoma_erbb2_immunohistochemistry_level_result |
|
metastatic_breast_carcinoma_estrogen_receptor_detection_method_text |
|
metastatic_breast_carcinoma_estrogen_receptor_level_cell_percent_category |
|
metastatic_breast_carcinoma_estrogen_receptor_status |
|
metastatic_breast_carcinoma_fluorescence_in_situ_hybridization_diagnostic_proc_centromere_17_signal_result_range |
|
metastatic_breast_carcinoma_her2_erbb_method_calculation_method_text |
|
metastatic_breast_carcinoma_her2_erbb_pos_finding_cell_percent_category |
|
metastatic_breast_carcinoma_her2_erbb_pos_finding_fluorescence_in_situ_hybridization_calculation_method_text |
|
metastatic_breast_carcinoma_her2_neu_chromosone_17_signal_ratio_value |
|
metastatic_breast_carcinoma_immunohistochemistry_er_pos_cell_score |
|
metastatic_breast_carcinoma_immunohistochemistry_pr_pos_cell_score |
|
metastatic_breast_carcinoma_lab_proc_her2_neu_immunohistochemistry_receptor_status |
|
metastatic_breast_carcinoma_lab_proc_her2_neu_in_situ_hybridization_outcome_type |
|
metastatic_breast_carcinoma_pos_finding_her2_erbb2_other_measure_scale_text | null |
metastatic_breast_carcinoma_pos_finding_other_scale_measurement_text | null |
metastatic_breast_carcinoma_pos_finding_progesterone_receptor_other_measure_scale_text | null |
metastatic_breast_carcinoma_progesterone_receptor_detection_method_text | null |
metastatic_breast_carcinoma_progesterone_receptor_level_cell_percent_category |
|
metastatic_breast_carcinoma_progesterone_receptor_status |
|
patient_id |
|
person_menopause_status |
|
person_neoplasm_cancer_status |
|
pgr_detection_method_text |
|
pos_finding_her2_erbb2_other_measurement_scale_text |
|
pos_finding_lymph_node_hematoxylin_and_eosin_staining_microscopy_count |
|
pos_finding_lymph_node_keratin_immunohistochemistry_staining_method_count |
|
pos_finding_metastatic_breast_carcinoma_estrogen_receptor_other_measuremenet_scale_text | null |
pos_finding_progesterone_receptor_other_measurement_scale_text |
|
positive_finding_estrogen_receptor_other_measurement_scale_text |
|
pretreatment_history |
|
primary_other_site_of_disease_name |
|
prior_diagnosis |
|
progesterone_receptor_level_cell_percent_category |
|
race |
|
radiation_therapy | null |
radiations | null |
surgical_procedure_purpose_other_text |
|
tissue_prospective_collection_indicator |
|
tissue_retrospective_collection_indicator |
|
tissue_source_site |
|
tumor_other_histologic_subtype_descriptive_text |
|
tumor_tissue_site |
|
vital_status |
|
year_of_initial_pathologic_diagnosis |
|
Page History
Overview
Content Tools